Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2014 4
2015 12
2016 12
2017 20
2018 25
2019 32
2020 28
2021 24
2022 25
2023 27
2024 18
2025 24
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.
Baraliakos X, Østergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado PM, Navarro-Compán V, Hermann KGA, Kishimoto M, Lee EY, Gensler LS, Kiltz U, Eigenmann MF, Pertel P, Readie A, Richards HB, Porter B, Braun J. Baraliakos X, et al. Arthritis Rheumatol. 2024 Aug;76(8):1278-1287. doi: 10.1002/art.42852. Epub 2024 Apr 30. Arthritis Rheumatol. 2024. PMID: 38556921 Clinical Trial.
OBJECTIVE: Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab ( …
OBJECTIVE: Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of th …
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Cañete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS. Gossec L, et al. Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531. Ann Rheum Dis. 2024. PMID: 38499325 Free PMC article.
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. Ward MM, et al. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21. Arthritis Care Res (Hoboken). 2019. PMID: 31436026 Free PMC article. Review.
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic trea …
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial …
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.
Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernández-Ávila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, O'Sullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A; GRAPPA Treatment Recommendations domain subcommittees. Coates LC, et al. Nat Rev Rheumatol. 2022 Aug;18(8):465-479. doi: 10.1038/s41584-022-00798-0. Epub 2022 Jun 27. Nat Rev Rheumatol. 2022. PMID: 35761070 Free PMC article. Review.
The overarching principles for the management of adults with PsA were updated by consensus. Principles considering biosimilars and tapering of therapy were added, and the research agenda was revised. Literature searches covered treatments for the key domains of PsA: periph …
The overarching principles for the management of adults with PsA were updated by consensus. Principles considering biosimilars and ta …
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, Ramiro S, van der Heijde D, Nikiphorou E. Webers C, et al. Ann Rheum Dis. 2023 Jan;82(1):130-141. doi: 10.1136/ard-2022-223298. Epub 2022 Oct 21. Ann Rheum Dis. 2023. PMID: 36270657 Free article.
OBJECTIVE: To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Al …
OBJECTIVE: To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axia …
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. Ward MM, et al. Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22. Arthritis Rheumatol. 2019. PMID: 31436036 Free PMC article.
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic trea …
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial …
GP2015: An Etanercept Biosimilar.
Deeks ED. Deeks ED. BioDrugs. 2017 Dec;31(6):555-558. doi: 10.1007/s40259-017-0246-1. BioDrugs. 2017. PMID: 28940172 Free PMC article. Review.
GP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylos …
GP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indicat …
SB5: An Adalimumab Biosimilar.
Frampton JE. Frampton JE. BioDrugs. 2018 Oct;32(5):507-510. doi: 10.1007/s40259-018-0307-0. BioDrugs. 2018. PMID: 30251234 Review.
SB5 (Imraldi( )) is a biosimilar of the reference anti-TNF monoclonal antibody adalimumab. It is approved for use in the following indications for which reference adalimumab is approved: rheumatoid arthritis (RA), juvenile idiopathic arthritis [polyarticular juvenile idiop …
SB5 (Imraldi( )) is a biosimilar of the reference anti-TNF monoclonal antibody adalimumab. It is approved for use in the following in …
Efficacy & safety of adalimumab biosimilar in axial spondyloarthritis: A retrospective study from a tertiary care centre in South India.
Gopalan A, Gavali M, Yerram K. Gopalan A, et al. Indian J Med Res. 2025 Nov;162(5):670-675. doi: 10.25259/IJMR_1780_2025. Indian J Med Res. 2025. PMID: 41520257 Free PMC article.
This study aimed to evaluate the efficacy and safety of adalimumab biosimilar in patients diagnosed with axial spondyloarthritis. Methods This retrospective, single-centre observational study from India assessed the efficacy and safety of adalimumab biosimilar …
This study aimed to evaluate the efficacy and safety of adalimumab biosimilar in patients diagnosed with axial spondyloarthritis …
Biologics for treating axial spondyloarthritis.
Jones A, Ciurtin C, Ismajli M, Leandro M, Sengupta R, Machado PM. Jones A, et al. Expert Opin Biol Ther. 2018 Jun;18(6):641-652. doi: 10.1080/14712598.2018.1468884. Epub 2018 May 7. Expert Opin Biol Ther. 2018. PMID: 29681195 Review.
INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton …
INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imag …
228 results